Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudolf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudolf, M.
(Chest. 2000;117:29S-32S.)
© 2000 American College of Chest Physicians

The Reality of Drug Use in COPD*

The European Perspective

Michael Rudolf, MD

* From the Ealing Hospital, London, UK.

Correspondence to: Michael Rudolf, MD, Department of Respiratory Medicine, Ealing Hospital, Uxbridge Rd, Southall, Middlesex UB1 3HW, UK

COPD guidelines provide advice about the appropriate use of various medications in treating patients with this condition. Comparisons of drug therapy as recommended by these guidelines with what is actually prescribed by both primary care physicians and specialist pulmonologists in a number of European countries can be examined in a variety of ways. Nonadherence to guidelines and differences between countries are caused by a number of factors, including varying degrees of misdiagnosis and different national attitudes to various classes of drugs.

Key Words: COPD • drug treatment • management guidelines




This article has been cited by other articles:


Home page
 Eur Respir JHome page
L. Huiart, P. Ernst, X. Ranouil, and S. Suissa
Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD
Eur. Respir. J., April 1, 2005; 25(4): 634 - 639.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Marchand
Survival in COPD patients after regular use of fluticasone propionate and salmeterol
Eur. Respir. J., March 1, 2003; 21(3): 559 - 560.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Roche, T. Lepage, J. Bourcereau, and P. Terrioux
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Eur. Respir. J., December 1, 2001; 18(6): 903 - 908.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.